Investigational drug · Phase 2
Vibostolimab
Also called: MK-7684
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Carcinoma, Non-Small-Cell Lung, Metastatic Urothelial Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
6
2 still active
All registered trials
20
Any phase or sponsor naming "Vibostolimab"
First trial start
2019
Dec 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vibostolimab", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Melanoma
- Carcinoma, Non-Small-Cell Lung
- Metastatic Urothelial Carcinoma
- Urothelial Neoplasms
- Carcinoma, Renal Cell
Approved drugs for the same conditions: Melanoma · Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Vibostolimab" as an intervention, largest first.
- A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05665595 · 1,594 participants · Start Jan 19, 2023 · Primary completion Mar 6, 2024
Drug: Pembrolizumab/Vibostolimab; Pembrolizumab · For: Melanoma
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 205 sites in all
- Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04738487 · 1,264 participants · Start Apr 7, 2021 · Primary completion Sep 5, 2024
Drug: Pembrolizumab/Vibostolimab; Pembrolizumab · For: Lung Neoplasms; Non-Small-Cell Lung Carcinoma
Sites: Boca Raton, Florida; Peoria, Illinois; Springfield, Missouri · 188 sites in all
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02861573 · 1,200 participants (planned) · Start Nov 17, 2016 · Primary completion Oct 22, 2027
Drug: Pembrolizumab 200 mg; Olaparib 400 mg and 10 more · For: Metastatic Castration-Resistant Prostate Cancer
- Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05226598 · 739 participants · Start Mar 24, 2022 · Primary completion Sep 24, 2024
Drug: Pembrolizumab/Vibostolimab; Carboplatin and 5 more · For: Metastatic Non-Small Cell Lung Cancer
Sites: Colorado Springs, Colorado; Fort Collins, Colorado; Jacksonville, Florida · 149 sites in all
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05007106 · 611 participants · Start Sep 16, 2021 · Primary completion Aug 5, 2025
Drug: Pembrolizumab/Vibostolimab Co-Formulation; Pembrolizumab and 10 more · For: Uterine Cervical Neoplasms; Endometrial Neoplasms; Squamous Cell Carcinoma of Head and Neck and 8 more
Sites: Anchorage, Alaska; Duarte, California; Orange, California · 73 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05298423 · 610 participants · Start May 3, 2022 · Primary completion Jun 15, 2026
Drug: pembrolizumab/vibostolimab; durvalumab and 5 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Long Beach, California; Los Angeles, California; Hollywood, Florida · 160 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02964013 · 474 participants · Start Dec 13, 2016 · Primary completion Jul 24, 2024
Drug: vibostolimab; pembrolizumab and 5 more · For: Neoplasms
- Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05224141 · 460 participants · Start Mar 24, 2022 · Primary completion Jun 4, 2024
Drug: Pembrolizumab/Vibostolimab Co-Formulation; Saline placebo and 4 more · For: Small Cell Lung Carcinoma
Sites: Mobile, Alabama; Los Angeles, California; Boca Raton, Florida · 140 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04165070 · 450 participants (planned) · Start Dec 19, 2019 · Primary completion Feb 13, 2032
Drug: Pembrolizumab; Carboplatin and 8 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Duarte, California; San Francisco, California · 47 sites in all
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626479 · 393 participants · Start Dec 16, 2020 · Primary completion Aug 10, 2026
Drug: Pembrolizumab; Favezelimab/Pembrolizumab and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 55 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Adjuvant anti-TIGIT plus anti-PD-1 in melanoma: A necessary failure that clarifies the path forward.
Ke Q, Zhou S · Transl Oncol 2026
- Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.
Sands J, Lu S, Aerts JG, et al. · Target Oncol 2026
- No RFS benefit found from adding vibostolimab to pembrolizumab in patients with high-risk melanoma: Adding the anti-TIGIT antibody vibostolimab to adjuvant pembrolizumab failed to improve recurrence-free survival and increased toxicity.
Lawrence L · Cancer 2026
- Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C.
Tetzlaff M, Taube JM, Long GV, et al. · ESMO Open 2026
- Beyond empiric checkpoint escalation: Insights from KEYVIBE-010.
Knight A, Sullivan RJ · Med 2026
- Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.
Dummer R, Guo J, Luke JJ, et al. · Lancet Oncol 2026
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.